Making Breakthroughs
in Medicinal Technology
We are thrilled to introduce you to our innovative product BPC 157. Developed by our team of experts at Diagen BPC 157 is a groundbreaking bioactive peptide that holds immense potential for enhancing health and well-being.
DIAGEN
About us
Diagen d.o.o. is a leading company dedicated to technological advancements in the development of new medicines. With a strong focus on research and innovation, we strive to push the boundaries of healthcare and improve patient outcomes.
- Collaborative Approach
- Rigorous Quality Control
- Ethical and Sustainable Practices
- Cutting-Edge Research
- Technological Expertise
- Focus on Patient Outcomes
Patents & Publications
At Diagen, we recognize that the future of healthcare lies in the intersection of technology and medicine. With our unwavering dedication to technological advancements, we strive to revolutionize the pharmaceutical landscape and improve patient outcomes. Join us on this journey as we explore new frontiers in drug development, protect intellectual property, and contribute to the scientific community through our patents and publications.
Patent 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Patent 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Publication 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Publication 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Unleashing the Power of Technological Innovation in New Drug Development
Prof. Predrag Sikirić, PhD
Prof. Dr. Predrag Sikirić, professor in School of Medicine, University of Zagreb is a leading scientist in Neurosciences, Dopamine application and gastrointestinal tract sciences. He is own many worldwide granted Patents and collaborates with Universities worldwide. He is reviewer and guest editor in many world renowned publications for Gastroenterology, Pharmacology, Neuropharmacology and others. He published 193 papers and 5380 citations. His main research area is discovery of BPC 157.
OUR TEAM
With a team of highly skilled scientists and researchers, Diagen leverages advanced technologies and techniques to drive the development of new medicines. Our technological expertise enables us to accelerate the discovery process and optimize therapeutic outcomes.
John Borthwick
Team member personal information
John Borthwick
Team member personal information
John Borthwick
Team member personal information
John Borthwick
Team member personal information